Thus, Inspire Medical Systems has an ROCE of 7.5%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 10%.

MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative ...

Inspire implants a neurostimulation device into your body to open airwaves. It's geared to those who have trouble with CPAP machines. The account was awarded after a competitive review.

Inspire Medical Systems has a 1 year low of $123.00 and a 1 year high of $256.11. The firm has a market capitalization of $4.76 billion, a P/E ratio of 92.42, a P/E/G ratio of 2.86 and a beta of 1.39.

Inspire Medical Systems (NYSE: NYSE:INSP), a medical technology company specializing in innovative solutions for obstructive ...

In the fourth quarter, Inspire said it brought on 72 new U.S. medical centers as customers, bringing its base to 1,435, and that it added 12 new sales territories to its more than 300 areas.

Inspire Medical Systems (NYSE:INSP), known for its innovative devices that use neurostimulation to treat sleep apnea, announced impressive fourth-quarter results on Feb. 10. Earnings per share ...

Inspire Medical Systems, Inc. (NYSE:INSP – Get Free Report) shares gapped down before the market opened on Monday . The stock had previously closed at $187.77, but opened at $182.00.

BofA upgrades Inspire Medical to Buy, setting a $255 price target. The company aims for $950 million in 2025 revenue, with a focus on new product launches and expansion.

BofA Securities has upgraded Inspire Medical Systems, Inc. (NYSE:INSP) and says the company now falls in the profitable growth category. Inspire Medical is expected to give its 2025 revenue ...

Play (1min) spawns Inspire Medical Systems (NYSE: INSP) traded higher on Wednesday after MedTech's CEO argued that the GLP-1 class of weight loss drugs could benefit its sleep apnea therapy business.